Revive Therapeutics (CSE: RVV) has provided an update to the market in regards to its psilocybin-based pharmaceutical program. Revive intends to utilize its patent-pending psilocybin formulations and its exclusive licensed drug delivery technology to investigate novel oral dosage forms of psilocybin, such as in the form of tablets or thin films like breath strips.
It has been found that several parallels exists between Revive’s IP portfolio of psilocybin-based formulations and that of the composites the firm studied with cannabidiol in the past when it comes to drug delivery mechanisms. As a result, Revive intends to research both methods together, as both provide unique qualities such as the potential for time release compositions and rapid on-set. To this end, Revive believes the most ideal delivery method will be that of an oral dissolvable tablet or an oral film strip, commonly referred to as a breath strip.
The firms psilocybin-based formulations have been created to synergistically work with the natural pathways of absorption found in the body. The current formulation development plans intend to pursue clinical studies for indications not currently being evaluated with psilocybin, while using the firms unique delivery platform IP as an advantage. For this, Revive will lean on its patent-pending technology that covers methods of producing psilocybin formulations as well as its extraction and crystallization methodologies.
Revive Therapeutics last traded at $0.14 on the CSE.
Sponsored · Emerita Resources Corp.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
One Response
Revive needs to add some gold to this play. Spice it up a little!